Phase Forward Signs Multi-Year Agreement with Quotient Clinical for Use of InForm Electronic Data Capture Solution

Phase Forward Signs Multi-Year Agreement with Quotient Clinical for Use of InForm Electronic Data Capture Solution

Specialist in Early Development Services Will Use InForm Product and Central Designer Module to Streamline Clinical Trial Delivery

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 5, 2009-- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year agreement with Quotient Clinical, which specializes in early development services for a broad range of pharmaceutical and biotech customers.

Quotient Clinical, a strategic business unit of Quotient Bioresearch ("Quotient"), is implementing Phase Forward's InFormTM Global Trial Management (GTM) electronic data capture (EDC) solution to support data collection, management and analysis for its clinical trials. In addition, the company will use Phase Forward's Central DesignerTM module to enhance eCRF design efficiency and improve workflow in the study development process for EDC trials.

"As an innovative provider of early drug development services, we want to ensure that our customers can take advantage of the benefits inherent in using EDC in Phase I trials, including access to high quality data within hours of collection, streamlined process efficiencies and rapid qualification of data," said Quotient's David Chalmers, vice president, Biometrics. "We selected InForm because of Phase Forward's strong position in the marketplace and the company's experience with Phase I trials."

By supporting faster accessibility and greater visibility into trial data, the EDC implementation will help Quotient to expand its full-service, in-house Biometrics offering, according to the company. In addition, Quotient plans to offer customers on-line access to trial data, making it easier for them to track progress to date or to review summary reports.

"Quotient's team is committed to continual expansion of its technical infrastructure to provide advanced services that help customers speed the development process," said Steve Powell, senior vice president, Phase Forward. "The organization joins the growing number of CROs adopting our InForm product as part of a broader initiative to automate and streamline their Clinical Research Units."

About Quotient Clinical

Quotient Clinical is a strategic business unit of Quotient Bioresearch. It was formed in May 2009 following the acquisitions of two companies, Charles River Laboratories' Edinburgh clinical research facility in May 2009 (formerly Inveresk Clinical Research) and Pharmaceutical Profiles in December 2008. Quotient Clinical specialises in early clinical drug development, and offers a unique streamlined process to reduce the time from First-in-Human studies through to proof of concept, integrating flexible drug product manufacture into clinical trials. With an existing strong customer base in the United States, Europe and Japan, the principal focus of Quotient Clinical is to provide a unique and comprehensive range of early development services to a broad range of pharmaceutical and biotechnology customers.

 

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.